Hordeolum
diseaseOn this page
Also known as blepharitis of eyelid glandeyelid gland blepharitisStye
Summary
Hordeolum (MONDO:0005800) is a disease with 11 GWAS associations across 5 studies and 2 clinical trials. Top therapeutic interventions include loteprednol etabonate, neomycin, and framycetin. A subtype of blepharitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 11
- Clinical trials: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hordeolum |
| Mondo ID | MONDO:0005800 |
| MeSH | D006726 |
| DOID | DOID:9909 |
| ICD-11 | 1259721857 |
| NCIT | C118722 |
| SNOMED CT | 397513003 |
| UMLS | C0019917 |
| MedGen | 6884 |
| Anatomy (UBERON) | UBERON:0013229 |
| Is cancer (heuristic) | no |
Also known as: blepharitis of eyelid gland · eyelid gland blepharitis · Stye
Data availability: 11 GWAS associations (5 studies).
Disease family
This is a subtype of blepharitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › eyelid disorder › blepharitis › hordeolum
Related subtypes (5): parasitic eyelid infestation, squamous blepharitis, noninfectious dermatoses of eyelid, blepharoconjunctivitis, ulcerative blepharitis
Subtypes (2): hordeolum externum, internal hordeolum
Genetics & variants
GWAS landscape
11 GWAS associations across 5 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| chr6:32440235 | 2e-13 | A | 0.11 | |
| chr19:18479133 | 5e-10 | T | 0.16 | |
| chr5:132227808 | 5e-09 | G | 0.08 | |
| chr22:43934316 | 1e-08 | T | 0.1 | |
| chr1:22967479 | 2e-08 | T | 0.1 | |
| chr11:1454158 | 3e-08 | GGGGGGGCTTACCTGT | 0.27 | |
| chr8:12788578 | 4e-08 | G | 0.08 | |
| chr15:87632757 | 4e-08 | A | 2.74 | |
| chr19:15872675 | 4e-08 | A | 0.08 | |
| chr3:66289862 | 4e-08 | G | 2.79 | |
| chr13:32318231 | 5e-08 | A | 3.37 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90473375 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 11,696 | 446,744 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90667808 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 11,696 | 446,744 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90079863 | Backman JD | 2021 | 4,139 | 377,132 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90083849 | Backman JD | 2021 | 4,139 | 377,132 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90473376 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 390 | 9,223 | Whole-genome sequencing of 490,640 UK Biobank participants. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 11 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 11 |
Functional consequences
| Consequence | Count |
|---|---|
| unknown | 11 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| chr6:32440235 | 2e-13 | Tier 4: intronic/intergenic | ||||||
| chr19:18479133 | 5e-10 | Tier 4: intronic/intergenic | ||||||
| chr5:132227808 | 5e-09 | Tier 4: intronic/intergenic | ||||||
| chr22:43934316 | 1e-08 | Tier 4: intronic/intergenic | ||||||
| chr1:22967479 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr11:1454158 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr8:12788578 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr15:87632757 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr19:15872675 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr3:66289862 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr13:32318231 | 5e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Gramicidin | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00420628 | PHASE4 | COMPLETED | Pediatric Zylet Safety and Efficacy Study |
| NCT00534391 | PHASE3 | UNKNOWN | Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LOTEPREDNOL ETABONATE | 4 | 1 |
| NEOMYCIN | 4 | 1 |
| FRAMYCETIN | 3 | 1 |
| CHEMBL3754093 | 0 | 1 |
| CHEMBL4299247 | 0 | 1 |
| VEHICLE | 0 | 1 |
Related Atlas pages
- Drugs: Loteprednol Etabonate, Neomycin, Framycetin